HIGHLIGHTS
- who: Jimena Ferraris from the Faculty of Medicine, University of Belgrade, Experimental (IBYME), Argentina have published the Article: Is prolactin receptor signaling a target in dopamine-resistant prolactinomas?, in the Journal: (JOURNAL)
SUMMARY
Pituitary neuroendocrine tumors (PitNETs), formerly pituitary adenomas, are systematized according to the 2022 WHO classification, accounting for the expression of transcription factors, hormones, and biomarkers. So, in the context of prolactinomas, what has sounded intuitively comprehensive has been that PRL, being elevated in the pathological context, could be contributing to prolactinoma proliferation and creating a positive loop: high PRL levels . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.